SG11201802895QA - Antibody/t-cell receptor chimeric constructs and uses thereof - Google Patents

Antibody/t-cell receptor chimeric constructs and uses thereof

Info

Publication number
SG11201802895QA
SG11201802895QA SG11201802895QA SG11201802895QA SG11201802895QA SG 11201802895Q A SG11201802895Q A SG 11201802895QA SG 11201802895Q A SG11201802895Q A SG 11201802895QA SG 11201802895Q A SG11201802895Q A SG 11201802895QA SG 11201802895Q A SG11201802895Q A SG 11201802895QA
Authority
SG
Singapore
Prior art keywords
antibody
cell receptor
chimeric constructs
receptor chimeric
constructs
Prior art date
Application number
SG11201802895QA
Inventor
Jingwei Lu
Zhiyuan Yang
Cheng Liu
Hong Liu
Yiyang Xu
Su Yan
Vivien Wai-Fan Chan
Lucas Horan
Original Assignee
Eureka Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eureka Therapeutics Inc filed Critical Eureka Therapeutics Inc
Publication of SG11201802895QA publication Critical patent/SG11201802895QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46448—Cancer antigens from embryonic or fetal origin
    • A61K39/464481—Alpha-feto protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464488—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
SG11201802895QA 2015-10-23 2016-10-21 Antibody/t-cell receptor chimeric constructs and uses thereof SG11201802895QA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562245944P 2015-10-23 2015-10-23
US201662304918P 2016-03-07 2016-03-07
US201662345649P 2016-06-03 2016-06-03
US201662369694P 2016-08-01 2016-08-01
PCT/US2016/058305 WO2017070608A1 (en) 2015-10-23 2016-10-21 Antibody/t-cell receptor chimeric constructs and uses thereof

Publications (1)

Publication Number Publication Date
SG11201802895QA true SG11201802895QA (en) 2018-05-30

Family

ID=58558140

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11201802895QA SG11201802895QA (en) 2015-10-23 2016-10-21 Antibody/t-cell receptor chimeric constructs and uses thereof
SG10201913247XA SG10201913247XA (en) 2015-10-23 2016-10-21 Antibody/t-cell receptor chimeric constructs and uses thereof
SG10201913245UA SG10201913245UA (en) 2015-10-23 2016-10-21 Antibody/t-cell receptor chimeric constructs and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201913247XA SG10201913247XA (en) 2015-10-23 2016-10-21 Antibody/t-cell receptor chimeric constructs and uses thereof
SG10201913245UA SG10201913245UA (en) 2015-10-23 2016-10-21 Antibody/t-cell receptor chimeric constructs and uses thereof

Country Status (16)

Country Link
US (6) US11421013B2 (en)
EP (2) EP3365364B1 (en)
JP (2) JP7316042B2 (en)
KR (1) KR20180063325A (en)
CN (4) CN107614519B (en)
AU (2) AU2016342041B2 (en)
CA (1) CA3001137A1 (en)
HK (2) HK1248243A1 (en)
IL (2) IL295398A (en)
MX (1) MX2018004721A (en)
MY (1) MY194628A (en)
PH (1) PH12018500861A1 (en)
RU (2) RU2022103665A (en)
SG (3) SG11201802895QA (en)
TW (2) TWI780031B (en)
WO (1) WO2017070608A1 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3227324A4 (en) 2014-12-05 2018-08-29 Memorial Sloan Kettering Cancer Center Antibodies targeting g-protein coupled receptor and methods of use
SG10202007326QA (en) 2014-12-05 2020-08-28 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof
AU2016342041B2 (en) 2015-10-23 2021-12-02 Eureka Therapeutics, Inc. Antibody/T-cell receptor chimeric constructs and uses thereof
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11307205B2 (en) 2016-09-19 2022-04-19 University Of Southern California Non-radioactive cytotoxicity assays
CN110352068A (en) * 2016-12-02 2019-10-18 南加利福尼亚大学 The immunity receptor and its application method of synthesis
CN110741016A (en) * 2017-04-26 2020-01-31 优瑞科生物技术公司 Chimeric antibody/T-cell receptor constructs and uses thereof
JP7295030B2 (en) 2017-04-26 2023-06-20 ユーリカ セラピューティックス， インコーポレイテッド Construct that specifically recognizes glypican 3 and use thereof
SG11202000025SA (en) * 2017-07-14 2020-02-27 Immatics Biotechnologies Gmbh Improved dual specificity polypeptide molecule
CN111315769A (en) * 2017-09-06 2020-06-19 加州理工学院 Dual-function receptor for signaling and antigen presentation (SABR)
MX2020003145A (en) * 2017-09-22 2020-07-29 Wuxi Biologics Ireland Ltd Novel bispecific polypeptide complexes.
SG11202002508XA (en) 2017-09-22 2020-04-29 Wuxi Biologics Ireland Ltd Novel bispecific cd3/cd19 polypeptide complexes
EA202090839A1 (en) * 2017-09-27 2021-02-04 Юниверсити Оф Саутерн Калифорния NEW COSTIMULATION PLATFORMS, NEW CAR DESIGNS AND OTHER IMPROVEMENTS FOR ADAPTIVE CELLULAR THERAPY
GB201718088D0 (en) * 2017-11-01 2017-12-13 Autolus Ltd Vectors
CN109971715A (en) * 2017-12-28 2019-07-05 深圳华大生命科学研究院 A kind of cultural method of specific amplification CAR-T cell
JPWO2019151392A1 (en) * 2018-01-31 2021-02-04 国立大学法人東北大学 Antigen-specific MHC expression regulation method
GB201801920D0 (en) * 2018-02-06 2018-03-21 Autolus Ltd Polypeptides and methods
US20220267420A1 (en) 2018-02-15 2022-08-25 Memorial Sloan Kettering Cancer Center Foxp3 targeting agent compositions and methods of use for adoptive cell therapy
SG11202008568WA (en) * 2018-03-09 2020-10-29 Sorrento Therapeutics Inc Dimeric antigen receptors (dar)
JP7404331B2 (en) * 2018-03-23 2023-12-25 ガビッシュ－ガリラヤ バイオ アプリケーションズ リミテッド Nucleic acid molecules encoding membrane-bound IL-10 and genetically reprogrammed Tregs expressing the same
JP7414226B2 (en) * 2018-03-30 2024-01-16 エウレカ セラピューティクス インコーポレイテッド Constructs targeting CD22 and their uses
CN110407927B (en) * 2018-04-26 2022-09-09 香雪生命科学技术（广东）有限公司 TCR (T cell receptor) capable of recognizing AFP (alpha fetoprotein) antigen
MX2020012927A (en) * 2018-06-01 2021-03-25 Univ Southern California Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy.
CA3103936A1 (en) * 2018-06-18 2019-12-26 Eureka Therapeutics, Inc. Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
CN110818802B (en) * 2018-08-08 2022-02-08 华夏英泰（北京）生物技术有限公司 Chimeric T cell receptor STAR and application thereof
CA3119968A1 (en) 2018-11-16 2020-05-22 Memorial Sloan Kettering Cancer Center Antibodies to mucin-16 and methods of use thereof
CN113286813A (en) * 2018-11-19 2021-08-20 得克萨斯大学体系董事会 Modular polycistronic vectors for CAR and TCR transduction
US20220098268A1 (en) * 2019-01-15 2022-03-31 Altor Bioscience, Llc Human immunodeficiency virus-specific t cell receptors
CN110006724B (en) * 2019-04-17 2021-06-04 郑州安图生物工程股份有限公司 Reagent for detecting trichomonas by adopting papanicolaou and gram staining method
DE102019121007A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigen binding proteins that specifically bind to MAGE-A
WO2021026266A1 (en) * 2019-08-05 2021-02-11 Distributed Bio, Inc. Antigen binding molecules and methods of screening thereof
WO2021030153A2 (en) * 2019-08-09 2021-02-18 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
CN114650829A (en) * 2019-09-05 2022-06-21 索伦托药业有限公司 Dimeric Antigen Receptor (DAR) that binds BCMA
AU2020344628A1 (en) * 2019-09-12 2022-04-07 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
CN116034113A (en) * 2019-12-30 2023-04-28 华夏英泰（北京）生物技术有限公司 Enhanced T cell receptor STAR and application thereof
AU2021205501A1 (en) * 2020-01-10 2022-08-18 TCR2 Therapeutics Inc. Compositions and methods for autoimmunity regulation
CN111320703A (en) * 2020-03-11 2020-06-23 北京双赢科创生物科技有限公司 Chimeric antigen receptor targeting CD22 and application thereof
JP2023518293A (en) 2020-03-20 2023-04-28 ライル・イミュノファーマ，インコーポレイテッド A novel recombinant cell surface marker
KR20230017786A (en) 2020-04-28 2023-02-06 라이엘 이뮤노파마, 인크. cell culture method
CN115715299A (en) * 2020-05-25 2023-02-24 华夏英泰（北京）生物技术有限公司 Enhanced synthetic T cell receptor antigen receptors
WO2022164959A1 (en) 2021-01-27 2022-08-04 Lyell Immunopharma, Inc. Improved immune cell therapy
KR20230150833A (en) 2021-02-25 2023-10-31 라이엘 이뮤노파마, 인크. Cell culture method
WO2022187591A1 (en) 2021-03-05 2022-09-09 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
EP4334361A1 (en) 2021-05-05 2024-03-13 Immatics Biotechnologies GmbH Antigen binding proteins specifically binding prame
CN117715929A (en) * 2021-07-29 2024-03-15 南特细胞公司 Modified T cell receptor for the prevention and treatment of viral infections and cancers
CA3228178A1 (en) 2021-08-05 2023-02-09 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
CA3230933A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
AU2022339667A1 (en) 2021-09-03 2024-04-11 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
WO2023070041A1 (en) 2021-10-21 2023-04-27 Lyell Immunopharma, Inc. Enhanced immune cell therapy
CA3234825A1 (en) 2021-10-28 2023-05-04 Lyell Immunopharma, Inc. Methods of generating cells
WO2023077026A1 (en) 2021-10-28 2023-05-04 Lyell Immunopharma, Inc. Methods for culturing cells expressing ror1-binding protein
US20230313138A1 (en) 2021-10-28 2023-10-05 Lyell Immunopharma, Inc. Methods for culturing cells expressing c-jun
WO2023133540A1 (en) 2022-01-07 2023-07-13 Lyell Immunopharma, Inc. Il-12 affinity variants
WO2024020429A1 (en) 2022-07-22 2024-01-25 Lyell Immunopharma, Inc. Immune cell therapy
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3753357A (en) 1970-12-14 1973-08-21 Ovitron Res Corp Method and apparatus for the preservation of cells and tissues
US4199022A (en) 1978-12-08 1980-04-22 The United States Of America As Represented By The Department Of Energy Method of freezing living cells and tissues with improved subsequent survival
US4559298A (en) 1982-11-23 1985-12-17 American National Red Cross Cryopreservation of biological materials in a non-frozen or vitreous state
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL86278A (en) * 1988-05-04 2003-06-24 Yeda Res & Dev Endowing cells with antibody specificity using chimeric t cell receptor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
DK0564531T3 (en) 1990-12-03 1998-09-28 Genentech Inc Enrichment procedure for variant proteins with altered binding properties
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5585358A (en) 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
EP0835306A1 (en) 1995-06-30 1998-04-15 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-mhc complex
DE19544393A1 (en) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistic herbicidal mixtures
AU757961B2 (en) * 1998-09-30 2003-03-13 Sankyo Company Limited Anti-Fas antibodies
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
EP1240319A1 (en) 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
ES2302726T3 (en) 2000-02-24 2008-08-01 Invitrogen Corporation STIMULATION AND SIMULTANEOUS CONCENTRATION OF CELLS.
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CN101289511A (en) 2000-04-11 2008-10-22 杰南技术公司 Multivalent antibodies and uses therefore
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
EP1334188B1 (en) 2000-11-07 2006-08-30 City of Hope Cd19-specific redirected immune cells
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
WO2003048731A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibody categorization based on binding characteristics
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
WO2003070752A2 (en) 2002-02-20 2003-08-28 Dyax Corporation Mhc-peptide complex binding ligands
EP2314622B1 (en) 2002-05-22 2017-10-18 ESBATech, an Alcon Biomedical Research Unit LLC Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
NZ556507A (en) 2002-06-03 2010-03-26 Genentech Inc Synthetic antibody phage libraries
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
WO2004106380A2 (en) 2003-05-31 2004-12-09 Micromet Ag Human-anti-human cd3 binding molecules
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
WO2005116072A2 (en) 2004-05-27 2005-12-08 Weidanz Jon A Antibodies as t cell receptor mimics, methods of production and uses thereof
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
EP1891113A2 (en) * 2005-06-02 2008-02-27 AstraZeneca AB Antibodies directed to cd20 and uses thereof
CA2611814A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP2009508517A (en) * 2005-09-22 2009-03-05 コーエン，イルン，アール Immunogenic fragments of T cell receptor constant domains and peptides derived therefrom
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
ES2547248T3 (en) 2006-04-28 2015-10-02 Delenex Therapeutics Ag Antibodies that bind to the extracellular domain of the ALK receptor tyrosine kinase
US20090304657A1 (en) * 2006-05-03 2009-12-10 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
EP2026837A4 (en) 2006-06-01 2010-06-02 Receptor Logic Inc Antibodies as t cell receptor mimics, methods of production and uses thereof
KR101456728B1 (en) 2006-09-08 2014-10-31 메디뮨 엘엘씨 Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2008137475A2 (en) 2007-05-01 2008-11-13 Research Development Foundation Immunoglobulin fc libraries
CN100592373C (en) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 Liquid crystal panel drive device and its drive method
UA121093C2 (en) 2008-06-25 2020-04-10 Атенікс Корпорейшн CONSTRUCTION CONTAINING TOXYGEN CODING A PESTICIDAL PROTEIN AND METHOD OF APPLICATION TO KILL SEMI-HARD-WINGED PESTS
PE20100362A1 (en) 2008-10-30 2010-05-27 Irm Llc PURINE DERIVATIVES THAT EXPAND HEMATOPOYETIC STEM CELLS
US20110286916A1 (en) 2008-11-20 2011-11-24 Jose Miguel Aste-Amezaga Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
US20100153133A1 (en) 2008-12-16 2010-06-17 International Business Machines Corporation Generating Never-Event Cohorts from Patient Care Data
WO2010091637A1 (en) 2009-02-10 2010-08-19 Shenogen Pharma Group Ltd. Antibodies and methods for treating estrogen receptor-associated diseases
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
AU2010277561A1 (en) 2009-07-30 2012-02-09 Helmholtz-Zentrum Fur Infektionsforschung Gmbh Compositions for generating an antigen specific immune response
CA2778533A1 (en) 2009-10-22 2011-04-28 Ricardo J. Moro Peptides that bind the alpha-fetoprotein (afp) receptor and uses thereof
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2012050374A2 (en) 2010-10-13 2012-04-19 Innocell, Inc. Immunotherapy for solid tumors
KR20140033029A (en) 2011-04-01 2014-03-17 메모리얼 슬로안-케터링 캔서 센터 T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
CN104379741B (en) 2012-04-23 2021-07-20 基因先端领域株式会社 Anti-human CD69 antibodies and their use for medical purposes
CN103319595B (en) 2012-07-04 2016-12-28 中国药科大学 Anti-human AFP single-chain antibody and the preparation method and application of fused antigen peptide
BR112015000638A2 (en) 2012-07-13 2017-08-08 Univ Pennsylvania isolated nucleic acid sequence, cell, methods for stimulating a cell-mediated immune response to a target cell or tissue population in a mammal, for providing antitumor immunity in a mammal, for treating a mammal having a disease, disorder or condition associated with high expression of a tumor antigen
US20150183877A1 (en) 2012-07-18 2015-07-02 Eli Lilly And Company Multi-Specific IgG-(Fab)2 Constructs Containing T-Cell Receptor Constant Domains
BR112015004522A2 (en) 2012-09-04 2017-11-21 Cellectis multi-chain chimeric antigen receptor and uses of these
EP3597215A1 (en) 2012-10-02 2020-01-22 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
CN102993305B (en) 2012-11-16 2015-05-13 上海赛伦生物技术有限公司 Humanized anti-human epidemic growth factor receptor (EGFR) antibody as well as encoding gene and application thereof
CA2894885A1 (en) 2012-12-13 2014-06-19 University Of Virginia Patent Foundation Target peptides for ovarian cancer therapy and diagnostics
CN103965362B (en) 2013-02-06 2019-02-01 上海细胞治疗集团有限公司 A kind of chimeric chemokine receptor for making T cell tend to tumor locus
JPWO2014123165A1 (en) 2013-02-06 2017-02-02 旭硝子株式会社 Transparent surface material and display device using the same
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
CN105208866B (en) 2013-03-21 2018-11-23 桑格摩生物治疗股份有限公司 Use engineering zinc finger protein nuclease targeted disruption T cell receptor gene
KR101536668B1 (en) 2013-06-18 2015-07-15 사회복지법인 삼성생명공익재단 Antibodies cross-reactive to Human and Mouse c-Met and Uses thereof
GB201313377D0 (en) 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
WO2015063069A1 (en) 2013-10-28 2015-05-07 Benjamin Felder Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors
CN104087592B (en) 2014-05-13 2016-01-27 天津医科大学总医院 AFP 158-166specificity TCR gene and transgenic T cells thereof and in-vitro multiplication method and purposes
CA2979732A1 (en) 2015-04-03 2016-10-06 Eureka Therapeutics, Inc. Constructs targeting afp peptide/mhc complexes and uses thereof
BR112017024757A2 (en) 2015-05-18 2018-11-13 TCR2 Therapeutics Inc. compositions and methods for reprogramming tcr using fusion proteins
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
WO2017004252A1 (en) 2015-06-30 2017-01-05 The Arizona Board Of Regents On Behalf Of The University Of Arizona Redirected cells with mhc chimeric receptors and methods of use in immunotherapy
JP7017015B2 (en) 2015-10-13 2022-02-08 エウレカ セラピューティクス インコーポレイテッド Antibodies specific to human CD19 and their use
AU2016342041B2 (en) 2015-10-23 2021-12-02 Eureka Therapeutics, Inc. Antibody/T-cell receptor chimeric constructs and uses thereof
CN105331585A (en) 2015-11-13 2016-02-17 科济生物医药（上海）有限公司 Chimeric antigen receptor-modified immunologic effector cell with PD-L1 blocking agent

Also Published As

Publication number Publication date
AU2016342041B2 (en) 2021-12-02
IL295398A (en) 2022-10-01
RU2018118652A3 (en) 2021-01-29
PH12018500861A1 (en) 2018-11-05
US11421013B2 (en) 2022-08-23
US20180085457A1 (en) 2018-03-29
EP3365364A1 (en) 2018-08-29
US20210253665A1 (en) 2021-08-19
EP3842450A1 (en) 2021-06-30
TW202321288A (en) 2023-06-01
WO2017070608A1 (en) 2017-04-27
JP7316042B2 (en) 2023-07-27
SG10201913245UA (en) 2020-02-27
RU2767209C2 (en) 2022-03-16
EP3365364A4 (en) 2019-08-07
US10822389B2 (en) 2020-11-03
MX2018004721A (en) 2018-07-06
JP2022050431A (en) 2022-03-30
US20190248865A1 (en) 2019-08-15
HK1258274A1 (en) 2019-11-08
KR20180063325A (en) 2018-06-11
CN115927191A (en) 2023-04-07
IL258405A (en) 2018-05-31
US20190022216A1 (en) 2019-01-24
CA3001137A1 (en) 2017-04-27
CN107614519B (en) 2022-08-05
HK1248243A1 (en) 2018-10-12
CN116059316A (en) 2023-05-05
US10098951B2 (en) 2018-10-16
CN107614519A (en) 2018-01-19
CN115925973A (en) 2023-04-07
RU2018118652A (en) 2019-11-26
SG10201913247XA (en) 2020-02-27
TW201730208A (en) 2017-09-01
US20220348629A1 (en) 2022-11-03
AU2022201334A1 (en) 2022-03-31
JP2019500848A (en) 2019-01-17
MY194628A (en) 2022-12-07
US10464988B2 (en) 2019-11-05
US20200115434A1 (en) 2020-04-16
AU2016342041A1 (en) 2018-04-19
IL258405B (en) 2022-09-01
RU2022103665A (en) 2022-03-05
EP3365364B1 (en) 2024-04-10
TWI780031B (en) 2022-10-11

Similar Documents

Publication Publication Date Title
HK1258274A1 (en) Antibody/t-cell receptor chimeric constructs and uses thereof
SG10201913579WA (en) Chimeric antibody/t-cell receptor constructs and uses thereof
IL274921A (en) Bcma-targeting chimeric antigen receptor, and uses thereof
EP3564266A4 (en) Novel chimeric antigen receptor and use thereof
IL254254A0 (en) Chimeric antigen receptor
AU2015269219B2 (en) Mesothelin-targeted chimeric antigen receptors and uses thereof
EP3256492A4 (en) Bi-specific chimeric antigen receptor and uses thereof
EP3259352A4 (en) Chimeric antigen receptors and uses thereof
GB201503742D0 (en) Chimeric antigen receptor
SG11201606790XA (en) Chimeric antigen receptor
FI3169703T4 (en) Chimeric antigen receptor and its use
GB201607968D0 (en) Chimeric antigen receptor
EP3347474A4 (en) Chimeric antigen receptors and uses thereof
GB201610512D0 (en) Chimeric antigen receptor
ZA201906321B (en) Chimeric antigen receptor
GB201709508D0 (en) Chimeric antigen receptor
GB2585607B (en) Chimeric antigen receptor and application thereof
GB201519900D0 (en) Chimeric antigen receptor
GB201810451D0 (en) Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof
GB201721421D0 (en) Chimeric antigen receptor
AU2015903719A0 (en) Chimeric antigen receptor and uses thereof
GB201612844D0 (en) Chimeric antigen receptor
GB201612533D0 (en) Chimeric antigen receptor
GB201604387D0 (en) Chimeric antigen receptor
AU2014902457A0 (en) Chimeric antigen receptor and uses thereof